Cellsway specializes in advanced liquid biopsy technologies, focusing on the detection and analysis of circulating tumor cells (CTCs) from blood samples. Their innovative microfluidic platform is designed to provide fast, sensitive, and effective cancer monitoring, enabling healthcare professionals to perform minimally invasive tests that facilitate better patient profiling. The company offers a range of products, including the CTC Enrichment Device and CTC Enrichment Chip, which utilize patented size-based enrichment techniques to isolate CTCs efficiently. This technology allows for streamlined workflows in clinical laboratories, significantly reducing hands-on time and enhancing reproducibility.

In addition to CTC enrichment, Cellsway provides various CTC identification panels that utilize immunofluorescence analysis to detect specific biomarkers, such as hormone receptors (ER/PR) and PD-L1, which are crucial for personalized cancer treatment. These panels are designed to support comprehensive cancer management by enabling the identification of tumor characteristics directly from blood samples. Overall, Cellsway's cutting-edge technologies represent a significant advancement in the field of cancer diagnostics, offering a game-changing approach to patient care through simple blood tests.

United Kingdom

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

Cellsway

Company Details